1. Scrip
  2. >>Therapy Areas

RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field

 
• By Joseph Haas

Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.

Although Alnylam Pharmaceuticals Inc.'s recent safety crisis with Phase III candidate revusiran suggests that RNA interference therapies remain a long way from the market, RXi Pharmaceuticals Corp. thinks it has a unique approach with a shorter, self-delivering form of RNAi therapeutic that can solve the delivery issue safely and get ideal penetration into targeted areas in dermatology and ophthalmology.

In an interview with Scrip, RXi's CEO Geert Cauwenbergh, formerly CEO of New Jersey dermatology specialty firm Barrier Therapeutics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.